Edgewise Therapeutics Inc (EWTX) Stock Price, Quote & News

Company Profile

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe...

Industry: Biotechnology

Sector: Healthcare

Phone: 720 262 7002

Website: edgewisetx.com

Address:

1715 38th Street, Boulder, United States

Quantumup Dec. 3 at 8:15 PM

JonesTrading⬆️ $CAPR's PT to $51 from $29,⬆️PoS to 80%, and reiterated at a Buy rating. $EWTX $PTCT $SRPT Here's what JonesTrading had to say in its note to investors: https://x.com/Quantumup1/status/1996311057824903227?s=20

1 · Reply

Guy8r Dec. 3 at 7:31 PM

$CAPR $PTCT $EWTX $SRPT Wainwright's $60 price target of CAPR based solely on Deramociel, imagine when stealthx, beckers, etc. gets priced in. Multi-bagger potential

1 · Reply

Quantumup Dec. 3 at 7:19 PM

H.C. Wainwright⬆️ $CAPR to $60 from $24, plus⬆️deramiocel's PoS to 90%, while reiterating at a Buy rating. $EWTX $SRPT $PTCT H.C. Wainwright said in its note: We reiterate our Buy rating and are increasing our price target to $60 from $24 based primarily on the following factors: (1) adjusting our fully diluted share count; (2) adjustment to base year; (3) reducing our discount rate to our usual 15% from 30%, which was initially based on the risk surrounding the CRL; and (4) increasing our projected chance of success for deramiocel to 90% from 75%. Our price target is based on our clinical net present value (NPV) model, which is driven entirely by the company's lead asset, deramiocel, in DMD patients. There is no contribution from added deramiocel indications or future potential exosomes candidates, which we believe represent potential upside to our valuation.

0 · Reply

hegdaom Dec. 3 at 3:16 PM

$CAPR $PTCT $SRPT $EWTX

0 · Reply

Quantumup Dec. 3 at 3:16 PM

B.Riley reiterated $CAPR at a Buy rating, and places price target under review pending its model update after Capricor Hit its Bull Case Scenario. $PTCT $EWTX $SRPT Here's what B.Riley had to say in its note to investors: https://x.com/Quantumup1/status/1996235575519494466?s=20

1 · Reply

Trainguy1 Nov. 29 at 3:19 PM

$EWTX One year ago the stock closed at $32.59. Since then, the company fully enrolled their ph3 Becker muscular dystrophy trial, and read out their ph2 HCM trial results. Although the HCM endpoints were positive, two participants experienced acute atrial fibrillation. The company said this is relatively common for certain HCM patients, but that they would add new exclusionary criteria to the upcoming phase 3 trial requirements in an attempt to prevent future AF events. In the meantime, EWTX has a 4-year cash runway of about a half billion dollars to progress their HCM and muscular dystrophy trials and MD pre-launch readiness. For more information, I recommend you review the Q3 business highlights linked below. BTW, the current average 12 month stock price forecast is $37, issued by primarily 4 and 5-star analysts. https://investors.edgewisetx.com/news/news-details/2025/Edgewise-Therapeutics-Reports-Third-Quarter-2025-Financial-Results-and-Recent-Business-Highlights/default.aspx

2 · Reply

S_Franconi Nov. 20 at 3:23 PM

$EWTX @Trainguy1 Prior to joining the Edgewise Board, Mr. Martin served as Chief Commercial Officer for Verona Pharma, which was acquired by Merck & Co. for approximately $10 billion in October of 2025. https://investors.edgewisetx.com/news/news-details/2025/Edgewise-Therapeutics-Appoints-Commercial-Biotech-Executive-Christopher-Martin-to-its-Board-of-Directors/default.aspx

2 · Reply

S_Franconi Nov. 20 at 3:22 PM

$EWTX Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors https://investors.edgewisetx.com/news/news-details/2025/Edgewise-Therapeutics-Appoints-Commercial-Biotech-Executive-Christopher-Martin-to-its-Board-of-Directors/default.aspx

0 · Reply

JianniMich Nov. 19 at 2:42 PM

$EWTX damn 0% change today, no buyers no sellers

0 · Reply

StockScanners Nov. 15 at 4:37 AM

$EWTX reached 24

0 · Reply

Edgewise Therapeutics, Inc. (EWTX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Dec 2, 2025, 8:00 AM EST - 3 days ago

Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules

Nov 20, 2025, 8:00 AM EST - 15 days ago

Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors

Nov 10, 2025, 8:00 AM EST - 25 days ago

Edgewise Therapeutics Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael Carruthers

Nov 7, 2025, 8:00 AM EST - 4 weeks ago

Edgewise Therapeutics to Participate in Upcoming Investor Conferences

Nov 6, 2025, 8:00 AM EST - 4 weeks ago

Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Oct 2, 2025, 8:00 AM EDT - 2 months ago

Edgewise Therapeutics to Present on Sevasemten for Becker and Duchenne Muscular Dystrophies at the 30th International Annual Congress of the World Muscle Society

Aug 14, 2025, 3:53 PM EDT - 4 months ago

Edgewise Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm

Aug 7, 2025, 8:00 AM EDT - 4 months ago

Edgewise Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Jul 19, 2025, 6:58 PM EDT - 4 months ago

EWTX Investors Have Opportunity to Join Edgewise Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Jun 26, 2025, 6:00 AM EDT - 5 months ago

Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies

Jun 3, 2025, 8:00 AM EDT - 6 months ago

Edgewise Therapeutics to Present at the Annual Goldman Sachs Global Healthcare Conference

May 14, 2025, 8:00 AM EDT - 7 months ago

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2025

May 8, 2025, 8:00 AM EDT - 7 months ago

Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 2, 2025, 7:07 PM EDT - 7 months ago

Why Edgewise Therapeutics Stock Popped This Week

Apr 10, 2025, 6:56 AM EDT - 8 months ago

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2

CAMP

Apr 2, 2025, 4:54 PM EDT - 8 months ago

Edgewise Therapeutics: Despite AF Safety Issues, EDG-7500 Advancement Presses On

Apr 2, 2025, 12:27 PM EDT - 8 months ago

Edgewise Therapeutics Sees Meaningful HCM Treatment Gains With EDG-7500 In Phase 2 Study

Apr 2, 2025, 6:22 AM EDT - 8 months ago

Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common Stock

Apr 2, 2025, 6:00 AM EDT - 8 months ago

Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM)

Mar 26, 2025, 4:45 PM EDT - 9 months ago

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time

Mar 11, 2025, 8:00 AM EDT - 9 months ago

Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference

Mar 10, 2025, 1:36 PM EDT - 9 months ago

Edgewise Therapeutics: More Expensive Now, But Much More Derisked

Mar 4, 2025, 8:00 AM EST - 9 months ago

Edgewise Therapeutics to Present at the Leerink Partners Global Healthcare Conference on March 11, 2025

Mar 3, 2025, 8:00 AM EST - 9 months ago

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Jan 22, 2025, 8:00 AM EST - 11 months ago

Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development

Jan 13, 2025, 8:00 AM EST - 11 months ago

Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025

Jan 7, 2025, 8:00 AM EST - 11 months ago

Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025

Dec 31, 2024, 2:09 PM EST - 1 year ago

Edgewise: Remains A Buy After Latest Becker Muscular Dystrophy Data

Dec 16, 2024, 11:56 AM EST - 1 year ago

Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease

Dec 16, 2024, 6:00 AM EST - 1 year ago

Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)

Dec 5, 2024, 2:32 PM EST - 1 year ago

Edgewise Provides Statement Regarding Company's Relationship with Dr. Han Phan at Rare Disease Research

Nov 26, 2024, 6:00 AM EST - 1 year ago

Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Oct 1, 2024, 8:00 AM EDT - 1 year ago

Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society

Sep 30, 2024, 12:12 PM EDT - 1 year ago

Analysts Think There's Still Time To Get In On Edgewise

Sep 25, 2024, 11:50 AM EDT - 1 year ago

Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge

Sep 19, 2024, 12:55 PM EDT - 1 year ago

Why Edgewise Therapeutics Stock Is Up 50% on Thursday

Sep 19, 2024, 10:19 AM EDT - 1 year ago

Edgewise Therapeutics Stock Shoots Higher On Promising Early Results For Thickened Heart Treatment

Sep 19, 2024, 7:00 AM EDT - 1 year ago

Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)

Sep 17, 2024, 4:01 PM EDT - 1 year ago

Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Aug 5, 2024, 2:38 PM EDT - 1 year ago

Edgewise Therapeutics: Strong Open Label Data Makes For A Bullish Signal

May 10, 2024, 8:00 AM EDT - 1 year ago

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024

May 9, 2024, 8:00 AM EDT - 1 year ago

Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

May 7, 2024, 8:00 AM EDT - 1 year ago

Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors

May 6, 2024, 8:00 AM EDT - 1 year ago

Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM)

Quantumup Dec. 3 at 8:15 PM

1 · Reply

Guy8r Dec. 3 at 7:31 PM

$CAPR $PTCT $EWTX $SRPT Wainwright's $60 price target of CAPR based solely on Deramociel, imagine when stealthx, beckers, etc. gets priced in. Multi-bagger potential

1 · Reply

Quantumup Dec. 3 at 7:19 PM

0 · Reply

hegdaom Dec. 3 at 3:16 PM

$CAPR $PTCT $SRPT $EWTX

0 · Reply

Quantumup Dec. 3 at 3:16 PM

1 · Reply

Trainguy1 Nov. 29 at 3:19 PM

2 · Reply

S_Franconi Nov. 20 at 3:23 PM

2 · Reply

S_Franconi Nov. 20 at 3:22 PM

0 · Reply

JianniMich Nov. 19 at 2:42 PM

$EWTX damn 0% change today, no buyers no sellers

0 · Reply

StockScanners Nov. 15 at 4:37 AM

$EWTX reached 24

0 · Reply

Gel021 Nov. 14 at 7:25 PM

$EWTX imo the next dump to $21, just whish good luck to the bulls

0 · Reply

Gel021 Nov. 14 at 7:15 PM

$EWTX nice candidate to short, waiting for an entry point

0 · Reply

JarvisFlow Nov. 14 at 3:44 PM

JP Morgan has updated their rating for Edgewise Therapeutics ( $EWTX ) to Overweight with a price target of 34.

1 · Reply

StockScanners Nov. 12 at 2:35 AM

$EWTX keep watch if this holds above 19.75

0 · Reply

chrsc Nov. 11 at 7:34 PM

$EWTX massive breakout! sweet!

1 · Reply

Quantumup Nov. 11 at 2:11 PM

RBC Capital⬆️the PT on $CYTK to $87 from $82, reiterated at an Outperform, and said, Updating Our Model Heading Into Aficamten 2026 Launch. $BMY $EWTX RBC Capital additionally said in its note: We recently caught up with mgmt to discuss expectations as CYTK heads into a highly anticipated launch of aficamten in 2026. We are updating our modeling assumptions on opex and revenues to better reflect what early U.S. launch dynamics in 2026 could look like following the Dec-'25 PDUFA, anchoring to historical competitor data. We continue to believe aficamten is likely to receive a differentiated REMS which can drive patient and physician preference, and enable the afi launch to outperform Camzyos and see >$2.6B in U.S. oHCM sales by 2034; our model changes bring our price target to $87.

0 · Reply

S_Franconi Nov. 10 at 4:17 PM

$EWTX Edgewise Therapeutics Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael Carruthers

0 · Reply

JarvisFlow Nov. 7 at 6:52 PM

RBC Capital has adjusted their stance on Edgewise Therapeutics ( $EWTX ), setting the rating to Outperform with a target price of 49 → 50.

1 · Reply

S_Franconi Nov. 7 at 5:26 PM

$EWTX BOULDER, Colo., Nov. 7, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will participate in the following investor conferences: Guggenheim 2nd Annual Healthcare Innovation Conference Fireside chat: Tuesday, November 11, 2025 at 8:30 am ET Piper Sandler 37th Annual Healthcare Conference Fireside chat: Tuesday, December 2, 2025 at 2 pm ET 8th Annual Evercore Healthcare Conference Fireside chat: Wednesday, December 3, 2025 at 3:25 pm ET https://investors.edgewisetx.com/news/news-details/2025/Edgewise-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences/default.aspx

1 · Reply

JarvisFlow Nov. 7 at 3:06 PM

Wedbush updates rating for Edgewise Therapeutics ( $EWTX ) to Outperform, target set at 35 → 32.

0 · Reply

d_risk Nov. 6 at 4:44 PM

$EWTX - Edgewise Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors EWTX’s latest 10-Q expands risk factors to highlight limited operating history, lack of approved products, delays or failures in developing sevasemten, EDG-7500, and EDG-15400, small patient populations, intense competition, manufacturing and regulatory hurdles, talent retention, compliance with anti-corruption laws, and increased detail on IP, cybersecurity, and third-party reliance. #Biotechnology #Cybersecurity #ProductDevelopment #RegulatoryRisk #PharmaceuticalDevelopment 🟢 Added 🟠 Removed https://d-risk.ai/EWTX/10-Q/2025-11-06

0 · Reply

haha1978 Nov. 3 at 11:30 PM

$EWTX $CPIX $SRPT $XBI with SRPT failing its 2 P3 studies what is there really left now? $CAPR

0 · Reply

Market Cap	2.43B
Revenue (ttm)	0.00
Net Income (ttm)	-133.81M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	940,200
Avg Vol	1,073,244
Day's Range	N/A - N/A
Shares Out	105.87M
Stochastic %K	35%
Beta	0.26
Analysts	Strong Sell
Price Target	$38.17